GLP1-Receptor Agonists for Prostate Cancer Treatment

Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

Recruiting Phase 4 Interventional Study
Prostate Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Male
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
20 (estimated)
Sponsor
Hamilton Health Sciences Corporation · Other
Who this trial is looking for

This trial is looking for men with prostate cancer who are receiving treatment to lower testosterone. Participants will take a medication called a GLP-1 receptor agonist to see how it affects their condition.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with prostate cancer.
  • I am receiving or plan to receive androgen deprivation therapy.
  • I have a higher body weight.

You may not be able to join if

  • I have type 1 diabetes.
  • I am taking a GLP-1 receptor agonist.
  • I am under 18 years old.
  • I have a history of pancreatitis.
  • I have a personal or family history of medullary thyroid cancer.
  • I have multiple endocrine neoplasia type 2.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Have a physician diagnosis of PC * Must be receiving or planned to receive ADT (gonadotropin releasing hormone agonist or antagonist ± androgen receptor pathway inhibitor) * Elevated BMI 1. ≥30kg/m2 or 2. ≥27kg/m2 in the presence of at least one of hypertension, type 2 di…
Contacts

Sarah Karampatos, BASc, MSc

905-296-5795

sarah.karampatos@phri.ca

CONTACT

Steven Agapay, BSc

905-296-5764

steve.agapay@phri.ca

CONTACT